Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

ArcticZymes Technologies launches T7 RNA Polymerase

Tromsø, Norway, December 21, 2023 – ArcticZymes Technologies ASA (OSE: AZT) launches T7 RNA PolymeraseArcticZymes Technologies (AZT) today announces the launch of its new product, T7 RNA Polymerase. Serving customers within the Molecular Tools segment, the T7 RNA Polymerase is intended for use in molecular research and diagnostics. The enzyme precedes the planned launch of a bioprocessing grade T7 RNA polymerase scheduled for 2024. The launch of the T7 RNA Polymerase is an example of ArcticZymes exploiting synergies between its business segments. While the field of RNA therapeutics is

Kemira Oyj: Proposals of the Nomination Board to the Annual General Meeting 2024

Kemira Oyj, Stock Exchange Release, December 21, 2023 at 9.00 am (EET)Kemira Oyj: Proposals of the Nomination Board to the Annual General Meeting 2024   The Nomination Board proposes to the Annual General Meeting of Kemira Oyj that eight members be elected to the Board of Directors and that the present members Tina Sejersgård Fanø, Werner Fuhrmann, Matti Kähkönen, Timo Lappalainen, Fernanda Lopes Larsen, Annika Paasikivi, Kristian Pullola and Mikael Staffas be re-elected as members of the Board of Directors. In addition, the Nomination Board proposes that Matti Kähkönen be re-elected

Elkem postpones start-up of Iceland furnace

Elkem will postpone the start-up of its furnace 3 on Iceland by one month. This follows a notice from the national power company about the need for electricity curtailment for large energy users due to low water levels in key hydropower reservoirs.Elkem’s furnace 3 on Iceland was temporarily shut down in the fourth quarter of this year in order to accelerate maintenance, with a ramp-down starting from 30 September. The planned start-up has now been postponed until the end of January 2024. This postponement will have no impact on customers or employees. The national power company,

Neste welcomes the French government’s ambition to increase the share of renewable energy in the transport sector

Neste Corporation, News, 21 December 2023Neste welcomes the French government and Senate’s decision to increase the share of renewable energy within the overall energy consumption of the transport sector. This decision will pave the way for important steps forward in the efforts to combat climate change.In January 2024, the required minimum share of renewable energy will increase from 8.6% to 9.2% to further accelerate greenhouse gas emission (GHG) reductions in the transport sector. This increase comes as a welcomed solution to support the transport sector’s decarbonization

Relais Group's financial reporting and Annual General Meeting in 2024

Relais Group Plc, Stock Exchange Release, 21 December 2023 at 9:00 a.m. EET Relais Group Plc will publish the following financial reports during 2024: · Financial Statements Review 2023, on Thursday, 7 March 2024 · Interim Report January–March 2024, on Wednesday, 8 May 2024 · Half-Year Financial Report January–June 2024, on Thursday, 15 August 2024 · Interim Report January–September 2024, on Thursday, 7 November 2024 The reports will be published at approximately 9:00 a.m. Finnish time on the above dates. Relais Group Plc’s Annual Reporting package 2023, which

Photocure ASA – Share option grant

Oslo, Norway, 20 December 2023 - Photocure ASA (the "Company") (OSE: PHO) cancels up to 1,400,428 options and has subsequently re-issued 399,000 options to employees. Up to 257,214 additional options are expected to be re-issued to employees in the near term, resulting in a net reduction of up to 744,214 options. 508,153 cancelled options were already vested, while all newly granted options will be replaced with options that are subject to a reset three-year vesting period, fully resetting the vesting period.A total of 399,000 share options, which vest over a three-year period, equal to 1.5%

Genetic Analysis partners up to enter the consumer market with GA-map®

OSLO, NORWAY - December 21, 2023: Today, Microbiome DX company Genetic Analysis AS ("GA" or the "Company") announces a collaboration with Comono AS (“Comono”) to develop a digital business platform for microbiome testing for the consumer market. The digital platform is already in advanced development, and a Joint Venture (“JV”) will be set up to complete the development and commercialize the consumer offering with an expected launch in Q2 2024. This JV aims initially to target the Nordic consumer market through online sales. By combining GA’s validated testing platform and bacteria know-how

New Chairman of the Board of Directors of Handelsbanken Fonder

Anna Possne has been appointed as new Board member and Chairman of the Board of Directors of Handelsbanken Fonder AB, a position she will assume immediately. Anna Possne succeeds Michael Green, who will assume the position as President and Group Chief Executive Officer of Svenska Handelsbanken AB (publ) on 1 January. Anna Possne is Head of Products and Offerings within Handelsbanken, a position she will retain alongside her position as Chairman of the Board of Directors of Handelsbanken Fonder AB. For further information, please contact:Staffan Ringvall, Head of Corporate Governance,

Transaction in Own Shares

    21 December 2023 Vesuvius plc Share Buyback Programme – Transactions in Own Securities   Vesuvius plc (the "Company") announces that it has purchased the following number of its Ordinary Shares of 10p each from Jefferies International Limited (the “Broker”), pursuant to the terms of its Share Buyback Programme announced on 4 December 2023:   +---------------------------------------------------------------+----------+|Date of purchase: |20/12/2023|+----------------------------------------------------------

Hadean Ventures announces oversubscribed final close of Hadean Capital II – a fund dedicated to investments in life science start-ups across Europe

· Hadean Capital II closes at EUR 144m, substantially over target of EUR 125m, bringing the total committed capital of Hadean Ventures’ two funds to approx. EUR 230m · Strong support from existing investors as well as a number of new investors including EIF, KfW Capital and Tesi · Launched in September 2021, Hadean Capital II has so far invested in six companies · First portfolio company exit was achieved in 2023, exceeding expectations   Oslo, 21 December 2023. Hadean Ventures announced today the final close of Hadean Capital II at EUR 144m, substantially above target of EUR

UPM Biomedicals enters into distribution agreement with Brinter for GrowInk bioinks

(UPM, Helsinki, 21 December 2023 at 09:00 EET) – UPM Biomedicals, the forerunner in producing high quality nanofibrillar cellulose for life science and clinical applications, has signed an extensive distribution agreement for GrowInk™  bioinks with Brinter Inc, a Finnish-US medtech/biotech company focusing on the development of cartilage implants using their patented 3D bioprinting technology. The agreement grants Brinter Inc the distribution rights of GrowInk bioinks in United States, Canada, Mexico, Finland, Austria,

Heavy demand for central office premises at Wallenstam

Among Wallenstam’s larger recent office lets, a strong interest is being noted for central premises in Gothenburg at addresses such as Kungsportsavenyen, the Långgatan streets, Västra Hamngatan, Inom Vallgraven and Gårda. The tenants include businesses and companies within security, services, accounting, consulting activities, specialists in surveillance solutions and the non-profit organization the Rescue Mission (Räddningsmissionen), which Wallenstam has supported since the outset in 1952.“We note a stable demand among both tenants that are growing and developing along with us and several

Enzymatica's Chairman to BioStock: "Our new research data makes 2024 an exciting year”

In 2023, Enzymatica presented important research results for ColdZyme and strengthened the marketing of the product. However, the sales growth has been lower than expected during the year, especially outside the company’s own markets. Despite this, the company remains committed to its long-term financial targets and looks ahead to what is to come in 2024. The company's Chairman of the Board, Bengt Baron, tells us more in an interview.Read the full article at biostock.se : https://www.biostock.se/en/2023/12/enzymaticas-chairman-our-new-research-data-makes-2024-

Skanska prepares for the expansion of emergency room in Miami, Florida, USA, for USD 90M, about SEK 960M

Skanska has signed a contract with Jackson Health System to prepare for the expansion of their emergency department (ED) through the demolition of two buildings. The contract is worth USD 90M, about SEK 960M, which will be included in the US order bookings for the fourth quarter of 2023.The scope of the contract is to create additional space for the approximately 12,100-square meter expansion, that includes construction of additional floors and that will triple the size of the health system’s flagship emergency department. It includes the renovation of the existing emergency room to match

Shape Robotics expects significant growth – guidance for 2024

Company announcement no. 43-23Copenhagen, Dec 21, 2023 The announcement contains inside information. Guidance 2024 Revenue DKK 300-325 millionEBITDA DKK 14-18 million Shape Robotics anticipates significant growth in 2024. The company expects to maintain the exponential revenue growth experienced thus far, continuing a trend since 2020. Additionally, despite anticipated large investments in development, Shape Robotics foresees a substantial increase in the EBITDA result. Assumptions and Conditions This growth is primarily expected to be driven by existing framework

Veidekke: To start construction of wind farm in Sweden for SR Energy

Veidekke and SR Energy are starting construction of the Vindpark Horshaga project in Uppvidinge, Sweden, having completed the project design phase. The project is a collaborative design and build contract, with a production phase contract value of approx. SEK 190 million. The wind farm is expected to start supplying electricity to the grid from late 2025.Veidekke's assignment comprises construction of roads, crane sites, internal power grids and foundations. Work on the project starts in early 2024 with the marking of assets worthy of conservation, before logging for roads and crane sites

Klingele, one of Germany´s largest paper & packaging manufacturer signs term sheet with Kyoto Group for Heatcube installation

Oslo, Norway 21 December 2023 - Kyoto Group is pleased to announce that it has signed a term sheet for delivering a Heatcube to one of Germany's major paper and packaging manufacturers—Klingele. The designated site for installing a first Heatcube is at Klingele’s facility in Werne, a corrugated board plant in Germany.Klingele Paper and Packaging Group, a global manufacturer with 13 corrugated board plants worldwide, 8 processing plants and 3 paper mills, aims to achieve a reduction of CO2 emissions by the year 2030. At the plant in Werne a reduction of 55% of CO2 emissions is planned by

Audientes A/S: Flagging notification

Company announcement no. 38-2023 December 20, 2023     Audientes A/S (“Audientes” or the “Company”), CVR 36047631, has today received information that the shareholder Michael O. Fehrn has, through the acquisition of further shares in the Company, again exceeded the threshold of ten (10) percent.   As of today, December 20, 2023, Michael O. Fehrn owns 6,277,398 shares, representing approximately 10.57 percent of the votes and capital in Audientes. The ownership is both direct and indirect through Fam. Fehrn Invest ApS.     For further information, please contact:

Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), today announced that the U.S. Food and Drug Administration (FDA) has approved TARPEYO (budesonide) delayed release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. TARPEYO was first approved in December 2021 under accelerated approval, based on the surrogate marker of proteinuria. Marking a significant milestone, TARPEYO is now the first fully FDA-approved treatment for IgAN based on a measure of kidney function.·

Notice to Extraordinary General Meeting in Metacon AB (publ)

The shareholders of Metacon AB (publ), org. no. 556724-1616 (the "Company"), are hereby invited to the extraordinary general meeting to be held on 24 January 2024 at 09.00 CET at Advokatfirman Schjødt, Hamngatan 27, Stockholm. Registration for the meeting commences at 08.30 CET. Right to participate and registration A shareholder who wish to participate in the general meeting must: (i) be entered in the register of shareholders maintained by Euroclear Sweden AB on 16 January 2024; and(ii) notified the Company of its attendance no later than 18 January 2024 to

Nordea Bank Abp: Repurchase of own shares on 20.12.2023

Nordea Bank AbpStock exchange release – Changes in company’s own shares20.12.2023 at 22.30 EET Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 20.12.2023 completed repurchases of own shares (ISIN: FI4000297767) as follows: +----------+-------+-------------------+-------------------+| Trading |Number | Weighted average |Total cost, EUR* **||venue (MIC| of |price / share, EUR*| || Code) |shares | ** | |+----------+-------+-------------------+-------------------+|XHEL |41,992 |11.15 |468,000.84

The Board of Directors in Metacon intends to resolve on a rights issue of approximately SEK 120 million

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL. PLEASE SEE "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.The Board of Directors of Metacon AB (publ) ("Metacon" or the "Company") today announces its intention to resolve on rights issue of units consisting of new shares and warrants of series TO 1, of approximately SEK 120 million (the “

Holding(s) in Company

TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN +------------+|GB00B635TG28|+------------+ Issuer Name +-----------+|ENQUEST PLC|+-----------+ UK or Non-UK Issuer +--+|UK|+--+ 2. Reason for Notification +-------------------------------------------+|An acquisition or disposal of voting rights|+-------------------------------------------+ 3. Details of person subject to the notification obligation Name +-----------------------------------+|Cobas Asset Management, SGIIC, S.A.|+---------------------------------

There are no items matching the current filter
There are no more items matching the current filter
Back to top